8-K: Calidi Biotherapeutics Updates Investor Presentation

Calidi Biotherapeutics, Inc. released an updated investor presentation on its website, furnished as Exhibit 99.1 to a Form 8-K.

Summary

• Calidi Biotherapeutics, Inc. (the "Company") filed a Form 8-K on August 29, 2025, to announce an updated investor presentation.
• The Company made an updated presentation available on its website on August 29, 2025.
• This presentation is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference.
• The information provided in this Item 7.01 disclosure, including Exhibit 99.1, is furnished under Regulation FD.
• The furnished information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities under that Section.
• The information will not be incorporated by reference into other Company filings under the Securities Act of 1933 or the Exchange Act, unless expressly set forth by specific reference.

Sentiment

Score: 5

Explanation: The filing is an administrative update announcing the availability of an updated investor presentation. It does not contain specific financial results, strategic developments, or operational changes that would significantly alter sentiment.

Future Outlook

NA

Management Comments

• The Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides access to updated company information through the presentation, aiding in informed decision-making.
• Investors: Offers new materials for due diligence and understanding company strategy and progress.

Key Dates

Keywords

Calidi Biotherapeutics, CLDI, Biotechnology, SEC Filing, 8-K, Investor Presentation, Regulation FD, Pharmaceuticals, Oncology